EMU003411
MISSION® esiRNA
targeting mouse Txnip
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
NACRES:
NA.51
UNSPSC Code:
41105324
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderdescription
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
CATGAGGCCTGGAAACAAATATGAGTACAAGTTCGGCTTCGAGCTTCCTCAAGGGCCCCTGGGAACATCCTTTAAAGGAAAATATGGTTGCGTAGACTACTGGGTGAAGGCTTTTCTCGATCGTCCCAGCCAGCCAACTCAAGAGGCAAAGAAAAACTTCGAAGTGATGGATCTAGTGGATGTCAATACCCCTGACCTAATGGCACCAGTGTCTGCCAAAAAGGAGAAGAAAGTTTCCTGCATGTTCATTCCTGATGGACGTGTGTCAGTCTCTGCTCGAATTGACAGAAAAGGATTCTGTGAAGGTGATGACATCTCCATCCATGCTGACTTTGAGAACACGTGTTCCCGAATCGTGGTCCCCAAAGCGGCTATTGTGGCCCGACACACTTACCTTGCCAATGGC
Ensembl | mouse accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
mouse ... TXNIP(56338), Txnip(56338)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Classe de stockage
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Lance A Thielen et al.
Cell metabolism, 32(3), 353-365 (2020-07-30)
Diabetes is characterized by hyperglycemia, loss of functional islet beta cell mass, deficiency of glucose-lowering insulin, and persistent alpha cell secretion of gluconeogenic glucagon. Still, no therapies that target these underlying processes are available. We therefore performed high-throughput screening of
Wei Li et al.
Current cancer drug targets, 14(4), 348-356 (2014-04-12)
Approximately 85% of pancreatic cancer patients suffer from glucose intolerance or even diabetes because high glucose levels can contribute to oxidative stress which promotes tumor development. As one of the reactive oxygen species (ROS)-regulating factors, thioredoxin-interacting protein (TXNIP), is involved